Lymphoma Clinical Trials

A listing of Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 12356 clinical trials
Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy

This prospective, open-label, single-arm study will evaluate the efficacy and safety of azacitidine in combination with chidamide in treatment of newly diagnosed peripheral T-cell lymphoma unfit for conventional chemotherapy.

lymphoma
tucidinostat
chidamide
t-cell lymphoma
measurable disease
  • 0 views
  • 19 Feb, 2024
  • 1 location
A Study to Evaluate the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of CN1

This study is the first-in-human clinical trial of CN1 to evaluate the safety, tolerability, pharmacokinetic (PK) profile and preliminary efficacy of CN1 in patients with advanced solid tumors or B-cell lymphoma. This study will provide a basis for further clinical development of CN1.

lymphoma
b-cell lymphoma
solid tumour
  • 0 views
  • 19 Feb, 2024
  • 1 location
A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy

A study of CT-RD06 cell injection in patients with relapsed or refractory CD19+ B-cell hematological malignancy.

ejection fraction
chronic lymphocytic leukemia
lymphoid leukemia
cancer
acute lymphoblastic leukemia
  • 0 views
  • 19 Feb, 2024
  • 1 location
A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

A study of CTA101 UCAR-T cell injection in patients with relapsed or refractory CD19+ B-line hematological malignancy

cell transplantation
ejection fraction
autologous hematopoietic stem cell transplant
chronic lymphocytic leukemia
lymphoblastic lymphoma
  • 0 views
  • 19 Feb, 2024
  • 1 location
Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL

This study will evaluate the efficacy and safety of camrelizumab in combination with apatinib in in patients with relapsed or refractory diffuse large B cell lymphoma failed from second line chemotherapy.

aptt
camrelizumab
pulse oximetry
ebv-positive dlbcl, nos
anticoagulant therapy
  • 0 views
  • 19 Feb, 2024
  • 1 location
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

This is a Phase I dose-finding study of FT596 as monotherapy and in combination with Rituximab or Obinutuzumab in subjects with relapsed/refractory B-cell Lymphoma or Chronic Lymphocytic Leukemia. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.

rituximab fludarabine
b-cell lymphoma refractory
contraceptive use
immunochemotherapy
antibody therapy
  • 0 views
  • 19 Feb, 2024
  • 3 locations
A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL

The phase II clinical study is to investigate the safety, tolerability, efficacy and pharmacokinetics of ICP-022.

lymphoma
b-cell lymphoma
primary cns lymphoma
diffuse large b-cell lymphoma
  • 0 views
  • 19 Feb, 2024
  • 5 locations
CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies

In this protocol, the investigators hypothesize that modifying the process of producing CAR+ T-cells can help to improve responses and reduce toxicities. Building on previous in vitro studies that have shown successful production of CAR+ T-cells using a new production approach, the investigators are now studying the ability to produce …

angina pectoris
primary immune deficiency disorder
adult acute lymphocytic leukemia
graft versus host disease
rheumatoid arthritis
  • 0 views
  • 19 Feb, 2024
  • 1 location
First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

Primary Objective: To determine the maximum tolerated dose (MTD) of SAR442257 administered as a single agent in patients with relapsed and refractory multiple myeloma (RRMM) and refractory non-Hodgkin lymphoma (RR-NHL), and determine the recommended Phase 2 dose (RP2D) Secondary Objectives: To characterize the safety profile of SAR442257 To characterize the …

cutaneous t-cell lymphoma
ejection fraction
dexamethasone
chronic lymphocytic leukemia
core needle biopsy
  • 0 views
  • 19 Feb, 2024
  • 5 locations
Lenalidomide in Combination With CHOP in Patients With Untreated PTCL

The prognosis of PTCL (except early stage ALK+ ALCL) is dismal. Previous study showed that single agent lenalidomide showed promising therapeutic activity in patients with relapsed or refractory PTCL. The investigators therefore design this phase II study to investigate the safety and efficacy of lenalidomide in combination with CHOP in …

lenalidomide
anaplastic large cell lymphoma
peripheral t-cell lymphoma
  • 0 views
  • 19 Feb, 2024
  • 1 location